"Receiving orphan drug designation from the FDA is a significant milestone for DiagnaMed and validates the promise of molecular hydrogen as a potential treatment for ALS. We are excited to partner ...
In addition to the patent, Revive also gets the intellectual and work property derived from DiagnaMed’s research activities ...
Revive Therapeutics (RVVTF) has entered into a non-binding letter of intent, dated February 28, 2025, to acquire the full rights to DiagnaMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results